Risk of dilution of share value through exercise of stock acquisition rights
First written in FY2017. 9 of 31 entries say "Restated". Latest entry: 2026-10-14.
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
0 other companies' latest entry also says "Cited as achieved".
- FY2026WorsenedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 1,300,400, equivalent to 21.0% of the 6,183,257 shares outstanding excluding treasury shares as of the same date.」
Potential shares increased from 1,220,800, or 20.2%, in the previous fiscal year to 1,300,400, or 21.0%, expanding dilution exposure. - FY2026-H1MaterialisedAnnual report
「During the current interim consolidated accounting period, capital and capital surplus each increased by ¥47.274 million as a result of issuing new shares following the exercise of part of the eighth series of stock acquisition rights.」
The partial exercise of the eighth series of stock acquisition rights resulted in the issuance of 150,000 shares, while capital and capital surplus each increased by ¥47.274 million. - FY2025WorsenedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 1,220,800, equivalent to 20.2% of the 6,033,257 shares outstanding excluding treasury shares as of the same date. If these stock acquisition rights are exercised, the value per share may be diluted.」
Potential shares totaled 1,220,800, equivalent to 20.2% of total shares outstanding, expanding dilution exposure from 936,000 shares, or 15.5%, in the previous fiscal year. - FY2024-Q2WorsenedAnnual report
「Eighth series of stock acquisition rights (third-party allotment) (issued 9 August 2023) Number of shares underlying the stock acquisition rights (shares): 510,700 The total number of shares underlying these stock acquisition rights is 510,700, equivalent to 8.41% of the 6,070,880 shares outstanding as of 31 May 2023. Ninth series of stock acquisition rights (third-party allotment) (issued 9 August 2023) Number of shares underlying the stock acquisition rights (shares): 194,100 The total number of shares underlying these stock acquisition rights is 194,100, equivalent to 3.20% of the 6,070,880 shares outstanding as of 31 May 2023.」
The eighth and ninth series of stock acquisition rights were newly issued, adding potential dilution exposure involving a total of 704,800 underlying shares, equivalent to 11.61% of total shares outstanding. - FY2024-Q1MaterialisedAnnual report
「20,000 6,070,880 6,000 1,223,581 6,000 1,200,031 (Note) The increase was due to the exercise of stock acquisition rights.」
During the first quarter, 20,000 shares were added through the exercise of stock acquisition rights, and capital and capital reserves each increased by ¥6 million. Share issuance associated with dilution has continued. - FY2023MitigatedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 936,000, equivalent to 15.5% of the 6,025,737 shares outstanding excluding treasury shares as of the same date,」
Potential shares remained at 936,000, the same as in the previous fiscal year, but the dilution ratio declined from 17.9% to 15.5% as total shares outstanding increased. - FY2022-Q3RestatedAnnual report
「Other stock acquisition rights, etc. Not applicable.」
The third-quarter report contains no new disclosures concerning other stock acquisition rights, etc. - FY2022-Q1RestatedAnnual report
「During the first quarter of the fiscal year, there were no occurrences of major risks that management recognizes could have a material effect on the financial position, operating results or cash flows of the consolidated companies, nor any material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no occurrences or material changes in the risk of dilution of share value through the exercise of stock acquisition rights. - FY2021WorsenedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 936,000, equivalent to 17.9% of the 5,225,697 shares outstanding excluding treasury shares as of the same date,」
Potential shares totaled 936,000, equivalent to 17.9% of total shares outstanding, expanding dilution exposure from 436,000 shares, or 8.5%, in the previous fiscal year. - FY2021-Q3RestatedAnnual report
「Other stock acquisition rights, etc. Not applicable.」
The third-quarter report contains no new disclosures concerning other stock acquisition rights, etc. - FY2021-Q2WorsenedAnnual report
「4 directors of the company Common shares 500,000 (Note 1)」
The seventh series of stock acquisition rights was granted to 4 directors of the company, adding 500,000 underlying shares as new potential shares. In addition to existing stock acquisition rights, this expanded the dilution exposure to the value of the shares. - FY2021-Q1RestatedAnnual report
「During the first quarter of the fiscal year, there were no occurrences of matters relating to the business or financial condition described in this quarterly report that could have a material effect on investors' decisions, nor any material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in the dilution risk associated with stock acquisition rights. - FY2020MitigatedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 436,000, equivalent to 8.5% of the 5,150,850 shares outstanding excluding treasury shares as of the same date,」
Potential shares declined from 445,000, or 8.7%, in the previous fiscal year to 436,000, or 8.5%, reducing the remaining dilution exposure. - FY2020-Q3RestatedAnnual report
「During the first nine months of the fiscal year, there were no occurrences of matters relating to the business or financial condition described in this quarterly report that could have a material effect on investors' decisions, nor any material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in the dilution risk associated with stock acquisition rights. - FY2020-Q2RestatedAnnual report
「During the first six months of the fiscal year, there were no occurrences of matters relating to the business or financial condition described in this quarterly report that could have a material effect on investors' decisions, nor any material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in the dilution risk associated with stock acquisition rights. - FY2019MitigatedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 445,000, equivalent to 8.7% of the 5,141,928 shares outstanding excluding treasury shares as of the same date. If these stock acquisition rights are exercised, the value per share may be diluted.」
Although stock acquisition rights continued to be exercised, potential shares declined from 499,000, or 9.81%, in the previous fiscal year to 445,000, or 8.7%, reducing the remaining dilution exposure. - FY2019-Q3MaterialisedAnnual report
「1 September 2018–30 November 2018 12,000 5,142,000 3,600 767,278 3,600 743,728 (Note) The increase was due to the exercise of stock acquisition rights.」
During the third quarter accounting period, 12,000 shares were added through the exercise of stock acquisition rights, bringing total shares outstanding to 5,142,000, while capital and capital reserves each increased by ¥3.6 million. Share issuance associated with dilution exposure has continued. - FY2019-Q2MaterialisedAnnual report
「The increase was due to the exercise of stock acquisition rights. 2. Between 1 September 2018 and 30 September 2018, the exercise of stock acquisition rights increased total shares outstanding by 12,000 shares and increased capital and capital reserves by ¥3.6 million each.」
During the second quarter accounting period, 2,800 shares were added through the exercise of stock acquisition rights, and a further 12,000 shares were issued in September 2018 before the filing date. Share issuance associated with dilution exposure has continued. - FY2019-Q1MaterialisedAnnual report
「Increase resulting from the exercise of stock acquisition rights.」
During the first quarter, 39,200 shares were added through the exercise of stock acquisition rights, meaning that part of the potential shares associated with dilution risk has materialized as actual share issuance. - FY2018WorsenedAnnual report
「As of the end of the current consolidated fiscal year, the number of potential shares from stock acquisition rights was 499,000, equivalent to 9.81% of the 5,088,000 shares outstanding as of the same date. If these stock acquisition rights are exercised, the value per share may be diluted.」
The company discloses 499,000 potential shares, equivalent to 9.81% of total shares outstanding, indicating that dilution exposure has increased from 2.2% in the previous fiscal year. - FY2018-Q3RestatedAnnual report
「During the first nine months of the fiscal year, there were no occurrences of matters relating to the business or financial condition described in this quarterly report that could have a material effect on investors' decisions, nor any material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes as a risk in relation to dilution from stock acquisition rights. Details of the fourth through sixth series of stock acquisition rights continue to be disclosed. - FY2018-Q2WorsenedAnnual report
「Number of stock acquisition rights: 2,000 Number of shares underlying the stock acquisition rights: 200,000 (a) If the total segment operating profit for the fiscal years ending February 2018 and February 2019 exceeds ¥500 million: exercisable portion 20% (b) If the total segment operating profit for the fiscal years ending February 2020 and February 2021 exceeds ¥800 million: exercisable portion 100%」
As subsequent events, stock acquisition rights from the fourth to the sixth series were granted, bringing the total number of underlying shares to 400,000. They are subject to performance conditions, expanding the dilution exposure from existing potential shares, but the disclosure does not state that actual share dilution has occurred. - FY2018-Q1RestatedAnnual report
「There have been no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in the dilution risk associated with stock acquisition rights. It separately describes the adjustment to the exercise price in connection with the stock split. - FY2017First statedAnnual report
「As of the end of the current fiscal year, the number of potential shares from stock acquisition rights was 57,000, equivalent to 2.2% of the 2,544,000 shares outstanding as of the same date. If these stock acquisition rights are exercised, the value per share may be diluted.」
The company discloses 57,000 potential shares from stock acquisition rights, equivalent to 2.2% of total shares outstanding, and describes the potential for dilution upon exercise.